Tuesday, June 30, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Prostate Cancer

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Tuesday, June 30
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.

 
 
Faculty

Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director
University of Virginia Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Kara M Olivier, NP, APRN-BC
Massachusetts General Hospital Cancer Center
Claire and John Bertucci Center for
Genitourinary Cancers
Boston, Massachusetts

Victoria Sinibaldi, RN, MS, CS, CANP, BC
Adult and Geriatric Nurse Practitioner
Research Associate in Oncology and Urology
Faculty, School of Medicine
Johns Hopkins University
Affiliate Staff, Johns Hopkins Hospital
Baltimore, Maryland

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Moderator

Neil Love, MD
Research To Practice
Miami, Florida


Topics for Discussion

  • Module 1: Optimal Integration of Novel Antiandrogens into the Management of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC)
  • Module 2: Recognizing and Managing the Side Effects of Hormonal Agents Used in the Management of PC
  • Module 3: Current and Emerging Strategies in the Management of Metastatic Hormone-Sensitive PC
  • Module 4: Current and Evolving Treatment Paradigms in Metastatic CRPC

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Apply existing and emerging research data to the therapeutic and supportive care of patients with early and advanced prostate cancer (PC).
  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant PC, and apply this information in the discussion of nonresearch treatment options with patients.
  • Counsel patients with hormone-sensitive metastatic PC about the use of cytotoxic and secondary hormonal therapy to ensure appropriate and informed shared decision-making.
  • Recognize how prior therapeutic exposure and patient and disease characteristics may affect the selection and sequencing of available systemic treatments for castration-resistant metastatic PC.
  • Describe the rationale for testing patients with metastatic PC for BRCA1/2 mutations and other related DNA damage repair pathway deficiencies, and advise individuals found to harbor these genetic abnormalities about available clinical trial data documenting the efficacy of PARP inhibition.
  • Educate patients about the side effects associated with approved therapies commonly employed in the management of advanced PC, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with PC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

A maximum of 1.5 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.



Participation Completion Requirements
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by USF Health, Research To Practice (RTP) or the ANCC. Any off-label use as declared by the FDA will be identified.

Disclosure Policy
USF Health adheres to ACCME and ANCC standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made in the activity syllabus.

USF Health — USF Health CPD staff have no relevant conflicts of interest to disclose.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Equal Opportunity Statement
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.

Contact Information
If you have questions regarding credit, please contact cpdsupport@usf.edu, or call 813-224-7860.

Supporters
This activity is supported by educational grants from Astellas and Pfizer, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.